NEW YORK (GenomeWeb) – Epigenomics today announced that the US Food and Drug Administration has requested further data before making a decision on whether to approve the firm's blood-based colorectal cancer screening test.

Epigenomics has received a response letter from the FDA providing guidance and recommendations for improving the pre-market approval application for the German molecular diagnostics firm's Epi proColon screening test. The FDA requested additional data showing that the test will increase compliance to colorectal cancer screening in the intended use population.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.